JACC has the details. Sitagliptin is a DPP-4 inhibitor used to treat type 2 diabetes. It’s sold in the U.S. as Januvia. Note that the alleged higher risk of heart failure is in patients who had a history of prior heart failure. Research findings like this are not always dependable or reproducible. It bears watching, especially if you’re a heart patient.
Tag Archives: Januvia
The four dipeptidyl-peptidase-4 inhibitors available in the U.S. are sitagliptin (sold as Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina). Vildagliptin is available in other countries.
Remember that drug names vary by country and manufacturer. This is a brief drug review; consult your physician or pharmacist for details.
How do they work?
DPP-4 inhibitors decrease both fasting and after-meal blood sugar levels primarily by increasing insulin release from pancreas beta cells. How they do it is complicated.
First off, you need to know that two gastrointestinal hormones levels—glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide—increase in response to a meal. These hormones increase insulin secretion by pancreas beta cells, suppress glucagon secretion from pancreas alpha cells after meals, help suppress glucose production by the liver, and improve glucose uptake by tissues outside the liver. GLP-1 also slows emptying by the stomach and reduces food intake. All this tends to lower glucose levels after meals.
Did I mention it was complicated?
If we could make these gut hormones hang around longer, their glucose-lowering action would be enhanced. How can we make them hang around and work longer? Easy: suppress the enzyme that degrades them: dipeptidyl-peptidase-4. That’s what DPP-4 inhibitors do.
The small intestine hormone GLP-1 is a major player in normal carbohydrate metabolism. GLP-1 levels, by the way, are decreased in type 2 diabetes.
For the DPP-4 inhibitors, we have no data on long-term safety, mortality, or diabetic complications.
Sitagliptin is FDA-approved as initial drug therapy for the treatment of type 2 diabetes, and as a second agent in those who do not respond to a single agent, such as metformin, a sulfonylurea, or a thiazolidinedione. It can also be used as a third agent when dual therapy with a sulfonylurea and metformin doesn’t provide adequate blood sugar control.
Saxagliptin, linagliptin, and alogliptin are FDA-approved as initial drug therapy for the treatment of type 2 diabetes (in adults) or as add-on drugs for those who do not respond to a single drug, such as metformin, a sulfonylurea, or a thiazolidinedione. In case you’re wondering, you wouldn’t use several of the DPP-4 inhibitors at the same time. In the summer of 2012, the FDA approved linagliptin as an add-on drug for type 2 diabetics already taking insulin. Linagliptin and alogliptin haven’t been studied in nursing or pregnant women; I’m not sure about sitagliptin and saxagliptin in those settings. Alogliptin is approved for combined use with metformin, pioglitazone, insulin, and perhaps sulfonylureas.
The DPP-4 inhibitors are given by mouth. The usual dose of sitagliptin is 100 mg once daily, with reduction to 50 mg for moderate to severe kidney impairment and 25 mg for severe kidney impairment. The usual dose of saxagliptin is 2.5 or 5 mg once daily, with the 2.5 mg dose recommended for patients with moderate to severe kidney impairment. Linagliptin’s dose is 5 mg daily, regardless of liver or kidney funtion. The alogliptin dose is 25 mg daily, with lower doses for those with kidney impairment.
Generally well-tolerated. No risk of hypoglycemia when used as the sole diabetes drug. They do not cause weight gain. Sitagliptin, linagliptin, and alogliptin might cause pancreatitis. Alogliptin may cause liver disease or abnormal liver function blood tests. Saxagliptin and alogliptin may increase the risk of heart failure, particularly in those with pre-existing heart or kidney disease.
Don’t use if you have . . .
. . . moderate or severe kidney impairment (sitagliptin) or severe kidney impairment (saxagliptin).
Use sitagliptin or alogliptin with caution and careful monitoring if you have a history of pancreatitis.
Updated April 7, 2016
Physicians now have an amazing array of drug therapies for control of type 2 diabetes. Until now, there has been no consensus as to which drugs to use, and when.
The American Association of Clinical Endocrinologists and the American College of Endocrinology have just issued a joint statement with specific drug recommendations. Their algorithm is quite detailed. Here are a few highlights you might not know about:
- Regular human insulin is not recommended
- NPH insulin is not recommended
- The following should be used earlier and more frequently: GLP-1 agonists (exenatide) and DPP-4 inhibitors (sitagliptin and saxagliptin)
- sulfonylureas are a lower priority
- metformin is still a key drug
In the U.S., exenatide is sold as Byetta; sitagliptin is Januvia; saxagliptin is Onglyza; metformin is Glucophage (among others).
If you have type 2 diabetes and are arguing with your physician about optimal drug therapy, this treatment algorithm may be a helpful tie-breaker.
Reference: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocrine Practice, 15 (2009): 540-559.